Abstract accepted to the Annual Meeting of the American Society of Clinical Oncology 2020

/ EnGeneIC Announces Acceptance of Abstract to the Annual Meeting of the American Society of Clinical Oncology 2020 Abstract Demonstrates Promising Early Results from Phase I/IIa study in Patients with Recurrent, Metastatic Pancreatic Cancer NEWS PROVIDED BY EnGeneIC Limited Jun 01, 2020, 08:05 ET  NEW YORK and SYDNEY, June 1, 2020 /PRNewswire/ -- EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV ™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that an abstract on the Phase I/IIa clinical trial with EGFR-targeted EDV nanocells in patients with recurrent, metastatic pancreatic cancer has been accepted at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientic Program, which will be held from May 29-31, 2020. The abstract, titled, "Interim Data: Phase I/IIa study of EGFR-targeted EDV nanocells carrying cytotoxic drug PNU-159682 (E-EDV-D682) with immunomodulatory adjuvant EDVs carrying α -galactosyl ceramide (EDV-GC) in patients with recurrent, metastatic pancreatic cancer," provides early data from nine patients in the ongoing open label Phase IIa study, the Carolyn Trial, in patients with treatment-refractory metastatic pancreatic cancer.  To date, the EDVs carrying the cytotoxic drug and immune adjuvant have been well tolerated and demonstrated an excellent safety prole. Further, early signs point to durable response in patients in this extremely difcult-to-treat patient population, possibly related to the development of an innate and adaptive immune response as a result of direct cytotoxic effects on drug resistant tumor cells.  / Professor Vinod Ganju, the Principal Investigator on the study at Frankston Private Hospital, Melbourne, said, "There have been no signicant advances in the treatment of pancreatic cancer and the mortality rate remains very high. The EDV therapeutic is showing a remarkable safety prole and some patients have had prolonged periods of disease control without toxicity. Currently, modications to dose and schedule are ongoing with the goal of achieving further substaintial improvement in anti-tumour efcacy." Dr. Himanshu Brahmbhatt, Joint-CEO of EnGeneIC, stated, "this is the rst time a super- cytotoxic drug designed to overcome serious multi-drug resistance in late stage cancers, has been safely delivered in patients. One aspect of the EDV's unique mechanism of action was recently published in Cancer Cell in March 2020 and the associated cover art depicts the cyto- immunotherapeutic pathway in pictorial form (Cancer Cell, 37: 354-370 (2020)." Details of abstract can be found at the ASCO Meeting Library. Abstract Number:  4632 Title:  "Interim Data: Phase I/IIa study of EGFR-targeted EDV nanocells carrying cytotoxic drug PNU-159682 (E-EDV-D682) with immunomodulatory adjuvant EDVs carrying α - galactosyl ceramide (EDV-GC) in patients with recurrent, metastatic pancreatic cancer" Session:  Gastrointestional Cancer, Gastroesophageal, Pancreatic, and Hepatobillary Trial: http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365258 About EnGeneIC and the EDV ™ Nanocell Technology  EnGeneIC is a clinical stage biopharmaceutical company advancing its proprietary bacterially- derived EDV ™ nanocells as a powerful nanoparticle drug, siRNA, or miRNA delivery platform designed to directly target and effectively kill tumor cells with minimal toxicity, while simultaneously stimulating the immune system's innate and adaptive anti-tumor response. First- and second-generation EDV ™  nanocells have shown promising results in early clinical studies and EnGeneIC is currently planning to commence further clinical trials in several cancer indications in Australia and USA. For more information, please visit www.engeneic.com.   / U.S. Investor Contact: Tiberend Strategic Advisors, Inc.  Miriam Weber Miller (Investors) +1-212-375-2694 [email protected] Johanna Bennett (Media) +1-212-375-2686 [email protected] Australia: EnGeneIC Ltd David Seaton +61 407 953 170 [email protected] SOURCE EnGeneIC Limited Related Links http://www.engeneic.com

The release as fetched from its publisher. engeneic.com ↗